A Study of MicroRNAs in Patients with Multiple Myeloma Treaded with Immunomodulatory Drugs


About this study

The purpose of this study is to explore how IMiD treatments affect certain genetic material called (microRNAs) in the body of patients with multiple myeloma. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Documented diagnosis of Multiple Myeloma
  • Adults > 18 years of age
  • Planned IMiD treatment in the coming months

Exclusion Criteria: 

  • Patients unable to give blood sample for research


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Xiu-Bao Chang, Ph.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer